Mankind Pharma Limited — PPTs, 23-01-2025: Investor Presentation

**Financial Highlights:** Mankind Pharma reported a robust revenue growth of 24% YoY, reaching INR 3,230 Cr in Q3FY25, driven by a strong performance in chronic therapies and an impressive 30% YoY growth in the OTC segment. Adjusted EBITDA climbed to INR 833 Cr, with a margin of 27.7%. However, PAT contracted by 16.4% YoY to INR 385 Cr due to one-time M&A related expenses.

**Strategic Initiatives and Growth Drivers:** The company has successfully integrated BSV, enhancing its product portfolio and operational efficiency. Mankind continues to focus on expanding its specialty and super specialty segments to sustain long-term growth.

**Business Developments:** Mankind has launched strategic initiatives that include entering niche areas within the chronic segment, with significant demand for products like insulin glargine and inhalers. The transition of the OTC business into a subsidiary aims to streamline operations and promote focused growth.

**Market Position and Competitive Advantage:** The acquisition of BSV has strengthened Mankind's market position, increasing its share from 4.4% to 4.8% in the IPM. The company maintains a leading position in the Gynae segment and continues to capitalize on high-growth potential products.

**Investor Implications:** The outlook appears positive, given the solid revenue growth and strategic positioning in specialty segments, indicating potential growth for investors looking to capitalize on the pharmaceutical sector's upward trajectory.